Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Characteristics of CD20×CD3 bispecifc antibodies

From: CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting

Agent

Format

CD20:CD3 ratio

Administration

FC silencing mutations

Dosing

Approved indications

Epcoritamab1

IgG1

1:1

SC

L234F, L235E, D265A (no FcγR, C1q binding)

Step-wise

LBCL and FL R/R after 2 or more lines

Glofitamab2

IgG1

2:1

IV

IgG1-P329G-LALA (no FcγR binding)

Step-wise

LBCL after 2 or more lines

Odronextamab5

IgG4

1:1

IV

Modified IgG4 (no FcγRIII binding)

Step-wise

Non approved for now

Mosunetuzumab12

IgG1

1:1

IV/SC

N297G (no FcγR binding)

Step-wise

R/R FL after 2 or more lines

Plamotamab8

IgG1

1:1

IV/SC

G236R, L328R (no FcγR binding)

Step-wise

Non approved for now

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us